Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1083

1.

High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.

Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D, Thomas R, Kholodenko D, Schenk D, Lieberburg I, Miller B, Green R, Basherad R, Kertiles L, Boss MA, Seubert P.

Arch Neurol. 1998 Jul;55(7):937-45.

PMID:
9678311
2.

Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice.

Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K.

Arch Neurol. 2001 Mar;58(3):373-9.

PMID:
11255440
3.

Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease.

Mehta PD, Pirttilä T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM.

Arch Neurol. 2000 Jan;57(1):100-5.

PMID:
10634455
4.

Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.

Sunderland T, Mirza N, Putnam KT, Linker G, Bhupali D, Durham R, Soares H, Kimmel L, Friedman D, Bergeson J, Csako G, Levy JA, Bartko JJ, Cohen RM.

Biol Psychiatry. 2004 Nov 1;56(9):670-6.

PMID:
15522251
5.

Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.

Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttilä T.

Arch Neurol. 2009 Mar;66(3):382-9. doi: 10.1001/archneurol.2008.596.

PMID:
19273758
6.

CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.

Smach MA, Charfeddine B, Lammouchi T, Harrabi I, Ben Othman L, Dridi H, Bennamou S, Limem K.

Neurosci Lett. 2008 Aug 1;440(2):145-9. doi: 10.1016/j.neulet.2008.05.076. Epub 2008 May 24.

PMID:
18555606
7.

Relationship between apoE genotype and CSF beta-amyloid (1-42) and tau in patients with probable and definite Alzheimer's disease.

Tapiola T, Pirttilä T, Mehta PD, Alafuzofff I, Lehtovirta M, Soininen H.

Neurobiol Aging. 2000 Sep-Oct;21(5):735-40.

PMID:
11016543
8.

Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment.

Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, Kurz A.

Arch Neurol. 2002 Nov;59(11):1729-34.

PMID:
12433260
9.

Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease.

Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, Vanderstichele H, Vanmechelen E, Blennow K.

Arch Neurol. 1999 Jun;56(6):673-80.

PMID:
10369305
10.

Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?

Clark CM, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D, Morris JC, McKeel DW Jr, Farlow M, Weitlauf SL, Quinn J, Kaye J, Knopman D, Arai H, Doody RS, DeCarli C, Leight S, Lee VM, Trojanowski JQ.

Arch Neurol. 2003 Dec;60(12):1696-702.

PMID:
14676043
11.

Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.

Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, Shen Y, Dodel R, Du Y, Farlow M, Möller HJ, Blennow K, Buerger K.

Mol Psychiatry. 2004 Jul;9(7):705-10.

PMID:
14699432
12.
13.

Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample.

Andreasen N, Minthon L, Clarberg A, Davidsson P, Gottfries J, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K.

Neurology. 1999 Oct 22;53(7):1488-94.

PMID:
10534256
14.

CSF biomarkers in relationship to cognitive profiles in Alzheimer disease.

van der Vlies AE, Verwey NA, Bouwman FH, Blankenstein MA, Klein M, Scheltens P, van der Flier WM.

Neurology. 2009 Mar 24;72(12):1056-61. doi: 10.1212/01.wnl.0000345014.48839.71.

PMID:
19307538
15.

Amyloid beta(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease.

Schoonenboom NS, Pijnenburg YA, Mulder C, Rosso SM, Van Elk EJ, Van Kamp GJ, Van Swieten JC, Scheltens P.

Neurology. 2004 May 11;62(9):1580-4.

PMID:
15136685
16.

Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.

Parnetti L, Tiraboschi P, Lanari A, Peducci M, Padiglioni C, D'Amore C, Pierguidi L, Tambasco N, Rossi A, Calabresi P.

Biol Psychiatry. 2008 Nov 15;64(10):850-5. doi: 10.1016/j.biopsych.2008.02.016. Epub 2008 Apr 8.

PMID:
18395699
17.

CSF tau is related to apolipoprotein E genotype in early Alzheimer's disease.

Tapiola T, Lehtovirta M, Ramberg J, Helisalmi S, Linnaranta K, Riekkinen P Sr, Soininen H.

Neurology. 1998 Jan;50(1):169-74.

PMID:
9443475
18.

Tau and Abeta42 protein in CSF of patients with frontotemporal degeneration.

Riemenschneider M, Wagenpfeil S, Diehl J, Lautenschlager N, Theml T, Heldmann B, Drzezga A, Jahn T, Förstl H, Kurz A.

Neurology. 2002 Jun 11;58(11):1622-8.

PMID:
12058089
19.

Decreased beta-amyloid peptide42 in cerebrospinal fluid of patients with progressive supranuclear palsy and corticobasal degeneration.

Noguchi M, Yoshita M, Matsumoto Y, Ono K, Iwasa K, Yamada M.

J Neurol Sci. 2005 Oct 15;237(1-2):61-5.

PMID:
15992827
20.

Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42.

Maddalena A, Papassotiropoulos A, Müller-Tillmanns B, Jung HH, Hegi T, Nitsch RM, Hock C.

Arch Neurol. 2003 Sep;60(9):1202-6.

PMID:
12975284

Supplemental Content

Support Center